Pfizer/Eyetech Macugen ASP
Pfizer/Eyetech's Macugen reimbursed at $1,054.70 per injection under Medicare Part B average sales price plus 6% model. Macugen, which FDA approved Dec. 17 for the treatment of neovascular (wet) age-related macular degeneration, carries a list price of $995 per injection (1"The Pink Sheet" Jan. 3, 2005, p. 7). Labeling recommends Macugen be administered every six weeks, bringing the treatment's annual cost based on list price to $7,960 per eye, and CMS' annual reimbursement per eye to $8,437.60 (2"The Pink Sheet" Jan. 10, 2005, p. 20)...
You may also be interested in...
The Macugen Access Program will help seniors cover the 20% Medicare copay, Eyetech COO Paul Chaney said
Pfizer/Eyetech's launch of the ophthalmic agent Macugen should be helped by a relatively generous initial reimbursement under Medicare Part B
A recent FDA action plan on artificial intelligence and machine learning (AI/ML) medical software could encourage more to jump in, said Eko Chief Medical Officer Adam Saltman.